Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email: natrajproteinItd@rediffmail.com CIN: L00153 MP 1990 PLC 006090

Online filing at www.listing.bseindia.com

Ref. :

NPL/SE/2022

Date:

30th May. 2022

To, The General Manager DCS-CRD **BSE LIMITED** Dalal Street, Fort, MUMBAI-400001

BSE Scrip CODE: 530119

Subject: Submission of the Audited Financial Results along with Auditors' Report thereon for the Quarter/Year ended 31st March, 2022 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am.

This is in continuation of our letter no. NPL/SE/2022 dated 18th May, 2022 regarding intimation for Board meeting for consideration and approval of the Quarterly/Yearly Audited Financial Results for the quarter/

Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Audited Financial Results along with Auditors' Report thereon by Statutory Auditors for the Quarter/Year ended on 31st March, 2022, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on 30th day of May, 2022.

Since, the Auditor's Report is self-explanatory and has no modification/qualification, it needs no further

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company www.natrajproteins.com.

The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format for that purpose.

You are requested to take on record the Audited Financial Results along with Auditor's Report for your

Thanking You, Yours Faithfully,

For, NATRAJ PROTEINS LIMITED

KAILASH CHAND SHARMA

CHAIRMAN & MANAGING DIRECTOR 217 S

DIN: 00012900

Encl.: Auditor's Report along with Standalone Audited Financial Results.



. ANUP SHRIVASTAVA & ASSOCIATES

ICAI FIRM REG.NO.006455C

CHARTERED ACCOUNTANTS

Independent Auditor's Report on the Standalone Audited Quarterly/Yearly Financial Results ended on 31.03.2022 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To.

The Board of Directors of NATRAJ PROTEINS LIMITED Itarsi (M.P.) 461111

Opinion

We have audited the accompanying Statement of quarterly and year to date Standalone Financial Results of NATRAJ PROTEINS LIMITED ("the Company"), for the Quarter and year ended 31" March, 2022 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, read with SEBI Circular CIF/CFD/FAC/62/2016 dated 5th July, 2016 (hereinafter referred to as the SEBI Circular); and
- (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31st March, 2022.

Basis for Opinion

We conducted our audit of the statement in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Act.Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Result" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

Management Responsibilities for the Standalone Financial Result

This Statement has been prepared on the basis of the Standalone Annual Audited Financial Statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS

RAMA COMPLEX,163, ZONE-I, S-1, SECOND FLOOR, M.P. NAGAR, BHOPAL 1462 011
*TEL.: 0755 -2555 642, FAX NO. 2573 291, E-Mail: anupassociates@gmail.com



ANUP SHRIVASTAVA & ASSOCIATES

ICAI FIRM REG.NO.006455C
CHARTERED ACCOUNTANTS

prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Result

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identity and assess the risks of material misstatement of the Statement, whether due to fraud
 or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis lot our opinion. The risk of not
 detecting a material misstatement resulting from fraud is higher than for one resulting from
 error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or
 the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we
 are also responsible for expressing our opinion on whether the Company has in place
 adequate internal financial controls with reference to financial statements and the operating
 effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the

CHARTERED

*TEL.: 0755 -2555 642, FAX NO. 2573 291, E-Mail: anupassociates@gmail.com



ANUP SHRIVASTAVA & ASSOCIATES

ICAI FIRM REG.NO.006455C

CHARTERED ACCOUNTANTS

audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions end events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the company to express an opinion on the Annual Standalone Financial Results

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the financial results for the quarter ended 31st March, 2022, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

Emphasis Matter

The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amount of receivables, unbilled revenues. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the company, as at the date of approval of this financial statement has used internal and external sources of information including subsequent payments received from debtors subsequent to the date of financial statements. The company based on current estimates expects the carrying amount of these assets will be recovered with extended credit period.

Our conclusion is not modified in respect of this matter.

For ANUP SHRIVASTAVA & ASSOCIATES FIRM REG NO. 006455C

CHARTERED ACCOUNTANTS

Place: - Bhopal

Date: - 30.05.2022

(CA ANUP SHRIVASTAVA) PARTNER

M.NO. 075270

UDIN:22075270AJWRVR7989

NATRAJ PROTEINS LIMITED

CIN: L00153MP1990PLC006090

Regd. Off. -Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111 Email: natrajproteinItd@rediffmail.com Website: www.natrajproteins.com

Statement of Standalone Audited Financial Results for the quarter and Year ended on 31st March, 2022

(Refer Notes Below) Income/Revenue from Operations II Other Income III Total Income (I+II) IV Expenses a Cost of Materials consumed by Purchase of stock-in-trade considered to the Changes in inventories of finished goods, work-in-progress and stock-in-trade demployee benefits expense effinance Costs Depreciation and amortization expense gother expenses Total Expenses (IV) Verofit / (Loss) before exceptional items and Tax (I-IV) VI Exceptional Items VII Profit / (Loss) before tax (V-VI)	31/03/2022	ended	3 months ended in the previous year	figures for current period ended	Previous year ended
Income/Revenue from Operations II Other Income III Total Income (I+II) IV Expenses a Cost of Materials consumed by Purchase of stock-in-trade consumed by Purchase of stock-in-trade consumed by Purchase of stock-in-trade descriptions of finished goods, work-in-progress and stock-in-trade descriptions descr		31/12/2021	31/03/2021	31/03/2022	31/03/2021
Operations Other Income III Total Income (I+II) IV Expenses a Cost of Materials consumed b Purchase of stock-in-trade c Changes in inventories of finished goods, work-in- progress and stock-in-trade d Employee benefits expense e Finance Costs f Depreciation and amortization expense g Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) VI Exceptional Items VII Profit / (Loss) before tax	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Operations Other Income Total Income (I+II) V Expenses Cost of Materials consumed Department of Stock-in-trade Changes in inventories of finished goods, work-in-progress and stock-in-trade Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) VI Exceptional Items VII Profit / (Loss) before tax					1
Other Income II Total Income (I+II) V Expenses Cost of Materials consumed Purchase of stock-in-trade Changes in inventories of finished goods, work-in-progress and stock-in-trade Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional Items Profit / (Loss) before tax	3240.92	4904.01	4677.85	14471.18	14621.62
Total Income (I+II) V Expenses Cost of Materials consumed Purchase of stock-in-trade Changes in inventories of finished goods, work-in-progress and stock-in-trade Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional Items Profit / (Loss) before tax	6.92	3.76	5.14	26.40	10.60
V Expenses Cost of Materials consumed Purchase of stock-in-trade Changes in inventories of finished goods, work-in- progress and stock-in-trade Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional ltems VII Profit / (Loss) before tax	3247.84	4907.77	4682.99	14497.58	14632.22
Cost of Materials consumed Purchase of stock-in-trade Changes in inventories of finished goods, work-in- progress and stock-in-trade Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (1-IV) Exceptional Items Profit / (Loss) before tax	3247.04	4207.77	4002.77	14427.50	14032.22
Purchase of stock-in-trade Changes in inventories of finished goods, work-in-progress and stock-in-trade Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional Items Profit / (Loss) before tax	2721.77	7011.00	42/2.00	10449.53	12004 52
Changes in inventories of finished goods, work-in-progress and stock-in-trade Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) VI Exceptional Items VII Profit / (Loss) before tax	2731.76	5311.82	4363.98	10448.52	13884.53
finished goods, work-in- progress and stock-in-trade d Employee benefits expense e Finance Costs f Depreciation and amortization expense g Other expenses Total Expenses (IV) V Profit / (Loss) before exceptional items and Tax (I-IV) VI Exceptional Items VII Profit / (Loss) before tax	840.14	527.43	262.15	1651.89	732.03
Employee benefits expense Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional Items Profit / (Loss) before tax		(1191.62)	(469.45)	220.08	(1089.66)
Finance Costs Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional Items VII Profit / (Loss) before tax	49.35	32.63	30.88	139.37	118.34
Depreciation and amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional Items VII Profit / (Loss) before tax		12.79	43.23	107.25	181.07
amortization expense Other expenses Total Expenses (IV) Profit / (Loss) before exceptional items and Tax (I-IV) Exceptional Items Profit / (Loss) before tax	52,18	12.79	43,23	107.23	101.07
Total Expenses (IV) V Profit / (Loss) before exceptional items and Tax (I-IV) VI Exceptional Items VII Profit / (Loss) before tax	9.96	9.88	10.07	39.60	40.25
V Profit / (Loss) before exceptional items and Tax (1-IV) VI Exceptional Items VII Profit / (Loss) before tax	227.17	164.57	251.92	595.25	667.88
Profit / (Loss) before exceptional items and Tax (1-IV) VI Exceptional Items VII Profit / (Loss) before tax	3749.05	4867.50	4492.78	13201.96	14534.44
VII Profit / (Loss) before tax		40.27	190.21	1295.62	97.78
	(# c			-	•
(* - * 1)	(501.21)	40.27	190.21	1295.62	97.78
VIII Tax expense					
1) Current Tax	(87.42)	7.18	12.96	341.68	12.96
2) Deferred Tax	15.34	1.31	(24.98)	(13.18)	(24.98)
3) Income tax related to earlier years			70.45	4.54	70.45
Profit / (Loss) for the period from continuing operations		31.78	131.78	936.22	39.35
(VII-VIII)		31.70	131.70	70,0122	
X Profit / (Loss) from Discontinuing operations			1 2		
XI Tax expenses from Discontinuing operations	-			×	
XII Profit / (Loss) from Discontinuing operations (after Tax) (X-XI)					
XIII Profit / (Loss) for the period (IX+XII)	e (429,13)	31.78	131.78	936.22	39.35
XIV Other Comprehensive Income: A (i) Items that will not be		(6.86)	3.27	4.29	5.07
reclassified to Profit or loss (ii) Income Tax relating to	(1.25)		(1.41)	(1.25)	(1,41)
items that will not be reclassified to Profit or loss B (i) Items that will be re classified to profit or loss					(8)
(ii) Income Tax relating to items that will b reclassified to Profit or loss				in its	B(-
XV Total Comprehensiv Income for the period (XII + XIV) (Comprisin profit/(Loss) and othe comprehensive income for the period)	e -		-		14

XVI	Paid-up Share Capital of the Company (Face Value of Rs. 10/- each)	374.70	374.70	374.70	374.70	374.70
XVII	Reserves Excluding Revaluation Reserves				4171.25	3231,98
XVIII	Earnings Per Share (for continuing operations)					
	(a) Basic	(11.45)	0.85	3.52	24.99	1.05
	(b) Diluted	(11.45)	0.85	3.52	24.99	1,05
XIX	Earnings Per Share (for Discontinued operations)					
	(a) Basic					
	(b) Diluted	12				
XX	Earnings Per Share (for Discontinued and continuing operations)					
	(a) Basic	(11.45)	0.85	3.52	24.99	1.05
	(b) Diluted	(11.45)	0.85	3,52	24.99	1.05

Notes :-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 30th May, 2022.
- 2. The Standalone Statement of Assets and Liabilities as at 31st March, 2022 and the Statement of Cash Flow Statement is provided as an annexure to this statement.
- 3. The company operates in two segments i.e. solvent extraction and commodities derivative trading. However, for the current quarter as well as corresponding quarter in previous year there is no requirement of segmental reporting as the sales of commodities/derivatives are less than the threshold limits.
- 4. The company has adopted Indian Accounting Standards (IND-AS) from 01.04.2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the Relevant rules made thereunder.
- 5. Statutory Auditors of the company have carried out Audit of the books of Account for the Financial Year 2021-2022 and issued us an Audit Report with Unmodified Opinion on Audited Financial Results for the Quarter/year ended 31.03.2022, therefore the company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion.
- 6. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- 7. Effective from 1st April, 2019, the company has adopted Indian Accounting Standard (IND-AS 116) "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2021 and there was no material impact on financial results for the quarter and year ended on 31st March, 2022.
- 8. The outbreak of Coronavirus (Covid 19) has disrupted economic activities across the world. However, the company continued to operate its manufacturing facilities and distribute its products which are covered under the essential commodities category. Though, there have been some operational difficulties due to lock down imposed in various regions, the impact on overall operations have not been significant. As the economic continues to remain highly uncertain, the management is regularly monitoring the development in countries where it operates or supplies goods and take necessary action to adapt to changing environment.

Date: 30.05.2022 Place: Itarsi KAILASH CHAND SH

Chairman & Managing Director

For, NATRAJ PROTEINS LIMIT

DIN: 00012900

STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS ON 31.03.2022

Statement of Assets and Liabilities	Nists Pierras - at the end of		(Rupees in Lakhs)	
Particulars	Note No.	Figures as at the end of current reporting period 31/03/2022	Figures as at the end of previous reporting period 31/03/2021	
		Audited	Audited	
ASSETS				
1) Non-Current Assets				
(a) Property, Plant and Equipment		411.86	265.83	
(b) Capital Work-in-Progress				
(c) Investment Property				
(d) Goodwill				
(e) Other Intangible assets				
(f) Intangible assets under development				
(g) Biological Assets other than bearer				
plants				
(h) Financial Assets				
i. Investments				
ii. Trade receivables		354.14	225.40	
iii. Loans		232.43	63.62	
iv. Others (to be specified)				
(i)Deferred tax assets(net)			1000	
(j) Other non-current assets		201.47	190.30	
Total Non-Current Assets		1199.90	745.2	
(2) Current Assets		2000.60	4510.7	
(a) Inventories		3990.69	4510.74	
(b) Financial Assets		(2.60		
i. Investments		63.68	1470.7	
ii. Trade receivables		1721.70	24.2	
iii. Cash and cash equivalents		482.20	24.2	
iv. Bank balances other than (iii) above		40.92	97.5	
v. Loans		40.83	91.3	
vi. Other (to be specified)		79.69		
(c) Current Tax Assets (Net)				
(d) Other current assets		6378.79	6103.2	
Total Current Assets	-	7578.69	6848.5	
Total Assets		7578.09	- GG TOLE	
EQUITY AND LIABILITIES				
Equity		374.70	374.7	
(a) Equity Share Capital		4171.25	3231.9	
(b) Other Equity				
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities		314.17		
(i) Borrowings				
(ii) Trade payables				
- Total outstanding dues of Micro and				
small enterprises;Total outstanding dues of creditors		6.61		
other than Micro and small				
enterprises; (iii)Other Financial liabilities (other than those				
specified in item (b), to be specified)				
(b) Provisions				
(b) Provisions (c) Deferred toy lightlities (Net)			70.0	
(c) Deferred tax liabilities (Net)		75.00	61.8	
(d) Other non-current liabilities Total Non-Current Liabilities			60	
		395.78	61.3	
(2) Current liabilities			2217	
(a) Financial Liabilities (i) Borrowings		2409.78	2217.0	

(ii) Trade payables		
- Total outstanding dues of Micro and		
small enterprises;		
- Total outstanding dues of creditors other than Micro and small	99.34	782.48
enterprises;		
(iii) Other Financial liabilities (other than		
those specified in item (c)		
(b) Other current liabilities	77.41	179.94
(c) Provisions		
(d) Current Tax Liabilities (Net)	50.43	
Total Current Liabilities	2636.96	3180.04
Total Equity and Liabilities	7578.69	6848.55

For, NATRAJ PROTEINS LIMITED

Date: 30.05.2022 Place: Itarsi

KAILASH CHAND SHARMA Chairman & Managing Director DIN: 00012900

Standalone Cash Flow Statement for the Year ended 31st March, 2022


(Rupees in Lakhs)

	(Rupees III	
	For the Year ended 31st March, 2022	For the Year ended 31st March, 2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
NET PROFIT BEFORE TAXATION AND EXTRAORDINARY ITEM	1295.62	97.78
ADJUSTMENT FOR:		
Depreciation and amortization expenses	39.60	40.24
Interest Paid	107.25	181.07
Interest Income	26.40	8.67
Others	38.64	24.98
Operating Profit before Working Capital Changes	1377.43	285.45
ADJUSTMENTS FOR		
Trade receivables	(250.93)	(88.44)
Inventories	391.37	(292.49)
loans, advances and other assets	(86.65)	153.07
Current liabilities	(536.46)	580.25
CASH GENERATED FROM OPERATIONS		
Income tax paid	(304.54)	37.54
Indirect tax paid		
Total Adjustments	(787.21)	566.80
NET CASH FROM OPERATING ACTIVITIES	590.22	852.25
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment, Intangibles etc,	(185.64)	(0.10)
Non-current Assets, Long-term Loans and Advances	(179.92)	(21.61)
Interest received	26.40	8.67
NET CASH USED IN/ FROM INVESTING ACTIVITIES	(339.16)	(13.04)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long-term borrowings	314.17	
Proceeds from Short-term borrowings/Banks		(868.10)
Interest paid	(107.25)	(181.07)
NET CASH USED IN/ FROM FINANCING ACTIVITIES	206.92	(1049.17)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	457.98	(209.97)
OPENING CASH AND CASH EQUIVALENTS	24.22	234.19
CLOSING CASH AND CASH EQUIVALENTS	482.20	24.22

For, NATRAJ PROTEINS LIMITED

Date: 30.05.2022 Place: Itarsi KAILASH CHAND SHARMA Chairman & Managing Director

DIN: 00012900



SOLVENT EXTRACTION PLANT & REFINERY Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email: natrajproteinltd@rediffmail.com CIN : L00153 MP 1990 PLC 006090

Online filing at www.listing.bseindia.com

Natraj

Ref.:

NPL/SE/2022

Date:

30th May, 2022

To. The General Manager DCS-CRD BSE LIMITED Dalal Street, Fort, MUMBAI-400001

BSE Scrip CODE: 530119

Subject: Submission of declaration as per Second proviso to the Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Financial Results for the year ended 31st March,

Dear Sir/Ma'am,

We hereby submit the following declaration regarding unmodified Auditors Report on the Audited Financial Results/Statements for the year 31st March, 2022 as audited by the Auditors of the Company.

DECLARATION

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated 25th May, 2016 and Circular No. CIR/CFD/CMD/56/ 2016 dated 27th May, 2016 and Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 issued by the SEBI. We. the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of the Company for the financial year ended on 31st March, 2022, the Auditor has not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the statement on impact of audit qualifications is not required to be given.

You are requested to please consider and take on record the same.

Thanking you, Yours faithfully,

0

D

S

or, NATRAJ PROTEINS LIMITED

CHAILASH CHAND SHARMA

CHAIRMAN &

MANAGING DIRECTOR

DIN: 00012900

Date: 30.05.2022 Place: Itarsi

CHIEF FINANCIAL OFFICER